What is the prevalence of Hereditary Hemorrhagic Telangiectasia?

Hereditary Hemorrhagic Telangiectasia (HHT), also known as Osler-Weber-Rendu syndrome, has an estimated prevalence of approximately 1 in 5,000 to 1 in 8,000 individuals worldwide. While often categorized as a rare disease, the true prevalence is likely higher due to significant underdiagnosis and the varied clinical presentation of Hereditary Hemorrhagic Telangiectasia across different populations.

What is the estimated prevalence of Hereditary Hemorrhagic Telangiectasia?

Current medical literature, including data from Orphanet and the NIH Genetic and Rare Diseases Information Center (GARD), suggests a prevalence of approximately 1 in 5,000 to 1 in 8,000 people. Because Hereditary Hemorrhagic Telangiectasia is a multisystem vascular disorder, many individuals remain asymptomatic or experience only mild symptoms like nosebleeds (epistaxis), leading to a significant number of undiagnosed cases. In our DiseaseMaps.org community, 141 members have identified as living with Hereditary Hemorrhagic Telangiectasia, providing a vital real-world perspective on the daily lived experience of this condition.

Does Hereditary Hemorrhagic Telangiectasia affect genders and ages equally?

Hereditary Hemorrhagic Telangiectasia is an autosomal dominant genetic condition, meaning it affects males and females with equal frequency. While it is a lifelong condition, the age of onset is highly variable. Many patients begin to show signs of Hereditary Hemorrhagic Telangiectasia in childhood, particularly with recurrent epistaxis, but the most severe vascular complications—such as pulmonary or cerebral arteriovenous malformations—often manifest or are diagnosed during adulthood. The clinical expression is notoriously heterogeneous, even among family members who share the same genetic mutation.

Are there geographic or ethnic variations in the occurrence of HHT?

Hereditary Hemorrhagic Telangiectasia is found globally across all ethnic and racial groups. There is no evidence suggesting that one specific geographic region or ethnicity is immune to the condition. However, certain populations may show higher reported rates due to founder effects or increased clinical awareness in specific regions. For example, some studies have noted higher prevalence in specific islands or isolated communities where the genetic mutation has been passed down through generations, but the fundamental genetic nature of Hereditary Hemorrhagic Telangiectasia remains universal.

Why is accurate prevalence data for Hereditary Hemorrhagic Telangiectasia difficult to obtain?

Determining the exact number of people with Hereditary Hemorrhagic Telangiectasia is challenging for several key reasons:

• Variable Expressivity: Symptoms range from mild, intermittent nosebleeds to life-threatening internal hemorrhages, causing many to never seek specialized medical attention.


• Underdiagnosis: Many physicians may not recognize the early clinical signs of Hereditary Hemorrhagic Telangiectasia, leading to misdiagnosis as common conditions like iron-deficiency anemia or chronic sinusitis.


• Lack of Universal Screening: In the absence of a family history, individuals may only be diagnosed after an acute vascular event, meaning many asymptomatic carriers remain uncounted in epidemiological studies.

Next steps

• Consult a specialist physician, such as a hematologist or a geneticist, if you have a family history or persistent symptoms of Hereditary Hemorrhagic Telangiectasia.


• Connect with the 141 peers on DiseaseMaps.org to share experiences and learn about regional HHT centers of excellence.


• Request a referral to a dedicated HHT Center of Excellence for comprehensive screening of arteriovenous malformations.


• Monitor for warning signs such as severe epistaxis, shortness of breath, or neurological changes, and discuss these with your care team immediately.

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• Orphanet: "Hereditary hemorrhagic telangiectasia" (ORPHA:774)


• NIH Genetic and Rare Diseases Information Center (GARD): "Hereditary Hemorrhagic Telangiectasia"


• OMIM (Online Mendelian Inheritance in Man): "Hereditary Hemorrhagic Telangiectasia, Type 1" (Entry #187300)


• Cure HHT: "About HHT - Prevalence and Statistics"